NewTradingView.com – Investing and Stock News
Investing and Stock News
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Investing

Should I sell Viatris shares after Q2 results failed to meet revenue expectations?

by August 14, 2022
written by August 14, 2022

Viatris Inc. (NASDAQ: VTRS) reported its second-quarter results on Monday and lowered the revenue outlook for the 2022 fiscal year.

Michael Goettler, CEO of Viatris, said that because of strong operational performance, he believes that Viatris can absorb the foreign exchange rate impact within announced ranges.

Q2 results failed to meet revenue expectations

Viatris is an American global healthcare company that produces and sells a variety of medicines, with 1,400 approved therapeutic molecules in its portfolio.

Viatris’s business remains stable, but the company reported weaker than expected second-quarter results this Monday. Total revenue has decreased by 10% Y/Y to $4.12 billion, while the GAAP earnings per share were $0.26.

Net sales from developed and emerging markets fell 6% Y/Y and 25% Y/Y to $2.5 billion and $650.9 million, while sales in China remained steady at $548.3 million compared to the second quarter of 2021.

Total revenue has decreased above expectations ( -$60 million), and the company lowered revenue guidance for the 2022 fiscal year. For the full year, Viatris expects total revenue to be in a range between $16.2 billion – $17.7 billion, while the prior outlook was revenue between $17 billion – $17.5 billion. Sanjeev Narula, Chief Financial Officer of Viatris, said:

Our revised revenue guidance takes into account foreign exchange impact through the first half of the year and approximately $600 million, split evenly between the third and fourth quarter of 2022. Operationally, we expect revenue will be driven by the continued ramp-up of new products, including the US launch of lenalidomide in the second half and the seasonality of Influvac in developed markets.

Despite this, the company’s management is proud of its financial performance in the second quarter and expects to deliver consistent and strong performance in the upcoming quarters.

According to the company’s management, the adjusted EBITDA for the 2022 fiscal year should be between $5.8 billion to $6.2 billion, while the free cash flow should be in a range between $2.5 billion and $2.9 billion.

Michael Goettler, CEO of Viatris, said that Viatris paid down approximately $1.5 billion in debt during the first half of the year and remains on track to achieve approximately $2 billion in debt repayment for the year.

Fundamentally looking, Viatris trades at less than three times TTM EBITDA, and with a market capitalization of $13.5 billion, shares of this company are not expensive.

Viatris’s balance sheet remains stable, the current dividend yield is around 4%, and shares of this company could provide strong returns for long-term investors.

Technical analysis

Viatris shares have advanced slightly above 14% since the beginning of August 2022, and the current price stands at $11.13.

Data source: tradingview.com

If the price jumps above $12, it will signal to trade Viatris shares, and the next target could be $13.

On the other side, if the price falls below the strong support that stands at $10, it would be a “sell” signal, and we have the open way to $9.

Summary

Viatris reported weaker than expected second-quarter results and lowered the revenue outlook for the 2022 fiscal year. Despite this, Viatris’s business remains stable, and the company’s management expects to deliver consistent and strong performance in the upcoming quarters.

The post Should I sell Viatris shares after Q2 results failed to meet revenue expectations? appeared first on Invezz.

0 comment
0
FacebookTwitterPinterestEmail

previous post
We Can’t Breathe!
next post
The FDA Has a Science Problem

You may also like

Disney Q1 earnings report: ‘this stock is unmatched...

February 9, 2023

Bank of America sees a 50% upside in...

February 8, 2023

Google stock loses 9.0% after it’s A.I event:...

February 8, 2023

Ex-Coinbase manager pleads guilty to insider trading charges

February 8, 2023

U.K. CMA issues provisional decision on Microsoft-Activision deal

February 8, 2023

Nasdaq 100 forecast – can index continue to...

February 8, 2023

Jim Cramer is bullish on Uber stock after...

February 8, 2023

Summary of Powell’s remarks and what it means...

February 8, 2023

Best undervalued Bill Ackman stocks for 2023

February 8, 2023

What’s happening to Chipotle stock in extended hours?

February 7, 2023
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Popular Posts

  • 1

    My Trigger to Enter $VAPR

  • 2

    Multi-Millionaire Trader Explains Why You Should Start Trading With A Small Account {VIDEO}

  • 3

    Scaling Up Tips From A 24-Year Old Millionaire Trader {VIDEO}

  • 4

    Pay Attention to These Stocks

  • 5

    New ‘Hunger Winter’ Looms as Europe Prepares to Shiver

Recent Posts

  • Disney Q1 earnings report: ‘this stock is unmatched anywhere else’

    February 9, 2023
  • Bank of America sees a 50% upside in this travel stock

    February 8, 2023
  • Google stock loses 9.0% after it’s A.I event: buy the dip?

    February 8, 2023
  • Ex-Coinbase manager pleads guilty to insider trading charges

    February 8, 2023
  • U.K. CMA issues provisional decision on Microsoft-Activision deal

    February 8, 2023

Categories

  • Economy (615)
  • Editor's Pick (235)
  • Investing (1,639)
  • Stock (9)
  • About Us
  • Email Whitelisting
  • Terms and Conditions
  • Privacy Policy
  • Contacts

Disclaimer: NewTradingView.com, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


Copyright © 2023 NewTradingView.com All Rights Reserved.


Back To Top
NewTradingView.com – Investing and Stock News
  • Investing
  • Stock
  • Economy
  • Editor’s Pick